---
document_datetime: 2025-12-29 12:35:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/klisyri.html
document_name: klisyri.html
version: success
processing_time: 0.1051174
conversion_datetime: 2025-12-31 07:47:08.385426
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Klisyri

[RSS](/en/individual-human-medicine.xml/67449)

##### Authorised

This medicine is authorised for use in the European Union

tirbanibulin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Klisyri](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Klisyri is an ointment used to treat adults with mild actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.

Klisyri contains the active substance tirbanibulin. It is available as 250-mg sachets, each containing 2.5 mg of tirbanibulin.

Expand section

Collapse section

## How is Klisyri used?

A thin layer of Klisyri is applied to the affected areas on the face or scalp once a day for five consecutive days. Klisyri should not be applied to open wounds or broken skin.

The patient's response to the treatment should be evaluated about 8 weeks after the start of treatment. If the actinic keratosis has not cleared completely at the time of evaluation, other treatment options should be considered.

The medicine can only be obtained with a prescription. For more information about using Klisyri, see the package leaflet or contact your doctor or pharmacist.

## How does Klisyri work?

The active substance in Klisyri, tirbanibulin, works by stopping cells in the skin growth from dividing and making new cells. It does so by attaching to a protein called tubulin, which is an important component of the cells' structural 'skeleton' (microtubules). This attachment stops the microtubules from growing, preventing especially the fast-growing cells from dividing and causing them to die.

Tirbanibulin also blocks certain enzymes called tyrosine kinases, which can be involved in cell division.

## What benefits of Klisyri have been shown in studies?

Two main studies, each involving 351 patients with actinic keratosis in the face and scalp, showed that Klisyri was effective in clearing actinic keratosis from the affected areas of the skin. Patients applied either Klisyri or placebo (a dummy treatment) on the affected areas for 5 days and were evaluated about 8 weeks (57 days) after starting treatment.

In the first study, actinic keratosis cleared completely in 44% of patients using Klisyri compared with 5% of those using placebo. Similarly, in the second study, actinic keratosis cleared completely in 54% of patients using Klisyri compared with 13% of the patients using placebo.

## What are the risks associated with Klisyri?

The most common side effects with Klisyri (which may affect more than 1 in 10 people) are local skin reactions, including erythema (reddening of the skin), flaking/scaling, crusting, swelling and the formation of sores and ulcers.

Other side effects with Klisyri (which may affect up to 1 in 10 people) are blisters, pruritus (itching) and pain at the application site.

For the full list of side effects and restrictions of Klisyri, see the package leaflet.

## Why is Klisyri authorised in the EU?

Two studies showed that that Klisyri was effective at clearing actinic keratosis from the affected skin of patients. The side effects were considered mild to moderate and were reversible. The European Medicines Agency therefore decided that Klisyri's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Klisyri?

The company that markets Klisyri must investigate the risk of actinic keratosis progressing to skin cancer following treatment in a 3-year safety study.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Klisyri have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Klisyri are continuously monitored. Suspected side effects reported with Klisyri are carefully evaluated and any necessary action taken to protect patients.

## Other information about Klisyri

Klisyri received a marketing authorisation valid throughout the EU on 16 July 2021.

Klisyri : EPAR - Medicine overview

Reference Number: EMA/356530/2021

English (EN) (118.09 KB - PDF)

**First published:** 21/07/2021

[View](/en/documents/overview/klisyri-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-50)

български (BG) (129.65 KB - PDF)

**First published:**

21/07/2021

[View](/bg/documents/overview/klisyri-epar-medicine-overview_bg.pdf)

español (ES) (107.07 KB - PDF)

**First published:**

21/07/2021

[View](/es/documents/overview/klisyri-epar-medicine-overview_es.pdf)

čeština (CS) (128.49 KB - PDF)

**First published:**

21/07/2021

[View](/cs/documents/overview/klisyri-epar-medicine-overview_cs.pdf)

dansk (DA) (106.59 KB - PDF)

**First published:**

21/07/2021

[View](/da/documents/overview/klisyri-epar-medicine-overview_da.pdf)

Deutsch (DE) (108.73 KB - PDF)

**First published:**

21/07/2021

[View](/de/documents/overview/klisyri-epar-medicine-overview_de.pdf)

eesti keel (ET) (95.63 KB - PDF)

**First published:**

21/07/2021

[View](/et/documents/overview/klisyri-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.54 KB - PDF)

**First published:**

21/07/2021

[View](/el/documents/overview/klisyri-epar-medicine-overview_el.pdf)

français (FR) (107.97 KB - PDF)

**First published:**

21/07/2021

[View](/fr/documents/overview/klisyri-epar-medicine-overview_fr.pdf)

hrvatski (HR) (127.89 KB - PDF)

**First published:**

21/07/2021

[View](/hr/documents/overview/klisyri-epar-medicine-overview_hr.pdf)

italiano (IT) (106.07 KB - PDF)

**First published:**

21/07/2021

[View](/it/documents/overview/klisyri-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (134.69 KB - PDF)

**First published:**

21/07/2021

[View](/lv/documents/overview/klisyri-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (127.4 KB - PDF)

**First published:**

21/07/2021

[View](/lt/documents/overview/klisyri-epar-medicine-overview_lt.pdf)

magyar (HU) (126.47 KB - PDF)

**First published:**

21/07/2021

[View](/hu/documents/overview/klisyri-epar-medicine-overview_hu.pdf)

Malti (MT) (128.59 KB - PDF)

**First published:**

21/07/2021

[View](/mt/documents/overview/klisyri-epar-medicine-overview_mt.pdf)

Nederlands (NL) (106.98 KB - PDF)

**First published:**

21/07/2021

[View](/nl/documents/overview/klisyri-epar-medicine-overview_nl.pdf)

polski (PL) (130.58 KB - PDF)

**First published:**

21/07/2021

[View](/pl/documents/overview/klisyri-epar-medicine-overview_pl.pdf)

português (PT) (107.02 KB - PDF)

**First published:**

21/07/2021

[View](/pt/documents/overview/klisyri-epar-medicine-overview_pt.pdf)

română (RO) (125.52 KB - PDF)

**First published:**

21/07/2021

[View](/ro/documents/overview/klisyri-epar-medicine-overview_ro.pdf)

slovenčina (SK) (128.52 KB - PDF)

**First published:**

21/07/2021

[View](/sk/documents/overview/klisyri-epar-medicine-overview_sk.pdf)

slovenščina (SL) (155.43 KB - PDF)

**First published:**

21/07/2021

[View](/sl/documents/overview/klisyri-epar-medicine-overview_sl.pdf)

Suomi (FI) (104.38 KB - PDF)

**First published:**

21/07/2021

[View](/fi/documents/overview/klisyri-epar-medicine-overview_fi.pdf)

svenska (SV) (105.91 KB - PDF)

**First published:**

21/07/2021

[View](/sv/documents/overview/klisyri-epar-medicine-overview_sv.pdf)

Klisyri  : EPAR - Risk management plan

English (EN) (957.99 KB - PDF)

**First published:** 21/07/2021

**Last updated:** 26/08/2025

[View](/en/documents/rmp-summary/klisyri-epar-risk-management-plan_en.pdf)

## Product information

Klisyri : EPAR - Product information

English (EN) (403.97 KB - PDF)

**First published:** 21/07/2021

**Last updated:** 19/09/2024

[View](/en/documents/product-information/klisyri-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-136)

български (BG) (511.45 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/bg/documents/product-information/klisyri-epar-product-information_bg.pdf)

español (ES) (394.35 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/es/documents/product-information/klisyri-epar-product-information_es.pdf)

čeština (CS) (407.33 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/cs/documents/product-information/klisyri-epar-product-information_cs.pdf)

dansk (DA) (401.91 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/da/documents/product-information/klisyri-epar-product-information_da.pdf)

Deutsch (DE) (412.83 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/de/documents/product-information/klisyri-epar-product-information_de.pdf)

eesti keel (ET) (393.09 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/et/documents/product-information/klisyri-epar-product-information_et.pdf)

ελληνικά (EL) (430.19 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/el/documents/product-information/klisyri-epar-product-information_el.pdf)

français (FR) (419.5 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/fr/documents/product-information/klisyri-epar-product-information_fr.pdf)

hrvatski (HR) (444.13 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/hr/documents/product-information/klisyri-epar-product-information_hr.pdf)

íslenska (IS) (407.47 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/is/documents/product-information/klisyri-epar-product-information_is.pdf)

italiano (IT) (397.49 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/it/documents/product-information/klisyri-epar-product-information_it.pdf)

latviešu valoda (LV) (410.26 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/lv/documents/product-information/klisyri-epar-product-information_lv.pdf)

lietuvių kalba (LT) (413.62 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/lt/documents/product-information/klisyri-epar-product-information_lt.pdf)

magyar (HU) (451.09 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/hu/documents/product-information/klisyri-epar-product-information_hu.pdf)

Malti (MT) (453.54 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/mt/documents/product-information/klisyri-epar-product-information_mt.pdf)

Nederlands (NL) (403.37 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/nl/documents/product-information/klisyri-epar-product-information_nl.pdf)

norsk (NO) (394.91 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/no/documents/product-information/klisyri-epar-product-information_no.pdf)

polski (PL) (444.46 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/pl/documents/product-information/klisyri-epar-product-information_pl.pdf)

português (PT) (409.68 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/pt/documents/product-information/klisyri-epar-product-information_pt.pdf)

română (RO) (437.1 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/ro/documents/product-information/klisyri-epar-product-information_ro.pdf)

slovenčina (SK) (431.81 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/sk/documents/product-information/klisyri-epar-product-information_sk.pdf)

slovenščina (SL) (433.41 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/sl/documents/product-information/klisyri-epar-product-information_sl.pdf)

Suomi (FI) (398.58 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/fi/documents/product-information/klisyri-epar-product-information_fi.pdf)

svenska (SV) (393.81 KB - PDF)

**First published:**

21/07/2021

**Last updated:**

19/09/2024

[View](/sv/documents/product-information/klisyri-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0020 17/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Klisyri : EPAR - All authorised presentations

English (EN) (38.62 KB - PDF)

**First published:** 21/07/2021

[View](/en/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-659)

български (BG) (50.81 KB - PDF)

**First published:**

21/07/2021

[View](/bg/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_bg.pdf)

español (ES) (58.98 KB - PDF)

**First published:**

21/07/2021

[View](/es/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_es.pdf)

čeština (CS) (45.74 KB - PDF)

**First published:**

21/07/2021

[View](/cs/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.41 KB - PDF)

**First published:**

21/07/2021

[View](/da/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (61.66 KB - PDF)

**First published:**

21/07/2021

[View](/de/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (57.2 KB - PDF)

**First published:**

21/07/2021

[View](/et/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.01 KB - PDF)

**First published:**

21/07/2021

[View](/el/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_el.pdf)

français (FR) (40.22 KB - PDF)

**First published:**

21/07/2021

[View](/fr/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (39.89 KB - PDF)

**First published:**

21/07/2021

[View](/hr/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (40.55 KB - PDF)

**First published:**

21/07/2021

[View](/is/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_is.pdf)

italiano (IT) (58.36 KB - PDF)

**First published:**

21/07/2021

[View](/it/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.25 KB - PDF)

**First published:**

21/07/2021

[View](/lv/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (44.2 KB - PDF)

**First published:**

21/07/2021

[View](/lt/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (61 KB - PDF)

**First published:**

21/07/2021

[View](/hu/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.32 KB - PDF)

**First published:**

21/07/2021

[View](/mt/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (42.85 KB - PDF)

**First published:**

21/07/2021

[View](/nl/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (62.76 KB - PDF)

**First published:**

21/07/2021

[View](/no/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_no.pdf)

polski (PL) (61.95 KB - PDF)

**First published:**

21/07/2021

[View](/pl/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.67 KB - PDF)

**First published:**

21/07/2021

[View](/pt/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.36 KB - PDF)

**First published:**

21/07/2021

[View](/ro/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.23 KB - PDF)

**First published:**

21/07/2021

[View](/sk/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.57 KB - PDF)

**First published:**

21/07/2021

[View](/sl/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (56.82 KB - PDF)

**First published:**

21/07/2021

[View](/fi/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (64.87 KB - PDF)

**First published:**

21/07/2021

[View](/sv/documents/all-authorised-presentations/klisyri-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Klisyri Active substance tirbanibulin International non-proprietary name (INN) or common name tirbanibulin Therapeutic area (MeSH) Keratosis, Actinic Anatomical therapeutic chemical (ATC) code D06BX03

### Pharmacotherapeutic group

Antibiotics and chemotherapeutics for dermatological use

### Therapeutic indication

Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.

## Authorisation details

EMA product number EMEA/H/C/005183

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Almirall, S.A.

Ronda General Mitre, 151

Opinion adopted 20/05/2021 Marketing authorisation issued 16/07/2021 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Klisyri : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.31 KB - PDF)

**First published:** 26/08/2025

[View](/en/documents/procedural-steps-after/klisyri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Klisyri : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (168.25 KB - PDF)

**First published:** 19/01/2022

**Last updated:** 26/08/2025

[View](/en/documents/procedural-steps-after/klisyri-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Klisyri : EPAR - Assessment report

Adopted

Reference Number: EMA/397273/2021

English (EN) (6.02 MB - PDF)

**First published:** 21/07/2021

[View](/en/documents/assessment-report/klisyri-epar-assessment-report_en.pdf)

CHMP summary of positive opinion for Klisyri

Adopted

Reference Number: EMA/CHMP/212648/2021 Corr

English (EN) (125.63 KB - PDF)

**First published:** 21/05/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-klisyri_en.pdf)

#### News on Klisyri

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021) 21/05/2021

**This page was last updated on** 26/08/2025

## Share this page

[Back to top](#main-content)